Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Make my userid true within the next 67 days!
JT, please sell as soon as you get formal approval for Europe. As much as I love you all, I’m ready to say good-bye to Amarin after hopefully $15 plus buyout
+1. Make my user name true! $15+ offer should be there within 60-90 days given the China, EMEA, and Prepare-it news.
JT, F-ing sell after EMEA approval so we can indeed have a prosperous 2021!
$7.25. GIA in EU and JT resisting buyout.
Filed in Delaware, is that good? What is the timing of next steps here?
JT should be required to take Hikma’s generic until he sells the company (or dies, so someone with a brain could sell it)
KEY TRANSCRIPT of what JT said today. Derek Archila
Got it. And then, maybe just to talk about the IP side of things and what you guys are doing. Maybe just give us an update on what you're doing in the U.S. And we get a lot of questions about the GSK, Teva lawsuit, I'm sure you guys do as well. And in terms of how that could read through to the VASCEPA kind of IP litigation in the case there?
John Thero
So, I first made reference to the fact that the litigation we’ve had in the United States pertains only to the United States. We've got regulatory exclusivity and other patents in Europe and other places in the world. And it pertains only to indication of treating patients with triglycerides greater than 500, not to the cardiovascular risk reduction indication. And we are continuing to pursue legal channels in the United States. We are certainly aware of -- I mean, our counsel was involved in representing GSK in the litigation that you've just referenced. I think, that there is -- that bears continuing to watch. I think, also, some of the regulations by things like Medicare also deserve to be watched relative to what is legal and illegal prescriptions of drugs, within approved labels. We have to see how the behavior is of the generics.
Derek Archila
Yes. I mean, is there like a script level or a market share level where it's like -- clearly, there's going to be awfully low use, beyond the label for the generics? But, is that something that it -- it sounds like you're watching it, but is there a threshold there that you guys…?
John Thero
No, comment. My counsel has told me to be -- not to say anything here that potentially could undermine our options from a legal perspective. And I'm going to refrain from that, other than to say that greater than 90% of our prescriptions are for cardiovascular risk reduction, not for treatment of very high triglycerides.
Derek Archila
Got it. Okay. That's fair. And then, I just wanted to close out with the U.S. discussion here before moving to EU. So, I know, Hikma has launched their generic in kind of a limited fashion. I think, they just raise their guidance by like 10 million for the entire year, to account for VASCEPA. But have we started -- as you guys are in the channel, and are you guys starting to see that come in? And, are there any other kind of just nuances that we should be paying attention to for some of maybe the other generics that could enter the market in the next 12 or so months? Just like what are you hearing kind of with your discussion with the wholesalers in terms of the generic launch?
John Thero
Hikma was the loudest up front, most direct and they were going to go first, and they have. They by their own public statements have commented about having limited supply and that their cost is higher than Amarin’s cost, which I think reflects our user experience building volumes. The other companies have been quieter. We are trying to keep ear open and figure out what people might be doing and when. But, I'm not going to speculate. Right now, we, based upon what we know, believe that we can outpace the growth in the United States of VASCEPA prescriptions versus what generics can supply
Let my name become a reality before we all lose our collective minds!
Dear BB, Fucking JT and his team of idiots should be helping you. You are working so much harder on finding a way to stop generics than Amarin team on payroll. Sad!
I would have dedicated a lot more $ towards the case. Hikma case had so many issues that went unnoticed. Cropped table, wrong Mori statistics should have been discovered by Amarin way before Bhatt. And I would have sold for $20 plus plus before Du verdict. I don’t believe a deal wasn’t available when everybody and their mom was convinced Amarin would prevail in Nevada.
It’s management’s responsibility for hiring Covington idiots. The buck stops with the CEO and the Board. Period, full stop.
Long-term investors would load up at $5 if it meant a double or triple within 12 months.
If AMRN is going to sell for $15+ why aren’t Baker Bros, and other institutions loading up on this no-brained double or triple opportunity?
Is this a serious question about JT missteps? Let’s start with filing a case in Nevada, not finding a way to settle, not selling to BP before Du verdict, and complete mishandling of that legal case including not doing the research Bhatt paper did on statistics and not noticing the cropped table.
You are right, sorry! Still $15 must not be on the table. I think $12.50 is more than fair given JT and company's missteps.
$15 is not on the table. JT rejecting 300% premium would be borderline criminal.
Vast majority of shareholders would take $12.50 and never miss JT and this shitshow. Let a capable BP bring this amazing drug to the masses
Miranda clearly has cum to the wrong conclusion because of silvery tongue and cropped slight of hand
Give me $12.50 within 3-6 months and I am a happy camper. Huge opportunity cost waiting for JT to potentially GIA in Europe until he finally sells years down the line.
Stock price predictions: 2020, 2021, 2222 end? Please post yours with assumptions. Mine:
2020 end: $5.25 — en Banc denied, Hikma enters
2021 end: $7.00 — GIA in Europe, slow sales uptake
2022 end: my name becomes a reality with a $12.50 buyout. $10 for ROW and $2.50 for USA
Thanks! So who will be handling those 2 cases you had mentioned? I assume they are a higher shot then Supreme Court? What is timing and odds in your esteemed opinion, sir?
What will happen to these after we get denied En Banc? Will that dumb bitch Du get them? Will she give Bhatt paper any consideration or just rule in favor of Hikma out of her Berkeley liberal lunacy spite?
Is November 2nd the last day for En Banc refusal? Can we assume if we don't hear by November 2nd, En Banc will be granted?
Make my name a reality, JT. Honestly, any buyout will be at least $12.50/share ($2.50 US and $10 ROW). That’s the absolute minimum. However, I don’t underestimate this company’s ability to screw up something with Europe approval or continuing the boneheaded GIA strategy. My concern isn’t the buyout price, it’s the fact that there may never be one.
Does each passing day raise your optimism that en banc will be granted?
Thanks! Does anyone know the deadline for outright En Banc denial based on this and other available info? Could 93 year old Judge Pauline Newman be our savior?
Perhaps we can mount an email campaign to JT? If someone eloquent can post a proposed draft text (we can modify the text before sending it from our respective emails) along with JT's email (+ any other relevant leaders that should be CC:ed), we can all email them. Strength in numbers! Imagine JT and Team receiving 100s of emails within 24 hours urging to sell the company for $10+.
Thank you! It was my first post, a 1 year bagholder. Let's hope my alias name comes true in 2021!
Wasn't the En Banc denial deadline today? Does this mean Newman or another judge stepped in to prevent the outright denial?